Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation (Q37256808)

19 August 2017

1 reference

title

Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation (English)

1 reference

19 August 2017

Ruriko Tanaka

1

1 reference

PubMed ID

18759691

19 August 2017

Shinya Kimura

series ordinal

2

1 reference

PubMed ID

18759691

19 August 2017

language of work or name

1 reference

1 September 2008

1 reference

Expert Review of Anticancer Therapy

19 August 2017

1 reference

19 August 2017

8

1 reference

19 August 2017

9

1 reference

19 August 2017

1387-1398

1 reference

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

19 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Resistance to imatinib mesylate in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Chronic myeloid leukemia: molecular monitoring in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Acute leukaemia in bcr/abl transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Chronic myeloid leukemia-still a few questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

How I treat chronic myeloid leukemia in the imatinib era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

A Src-like inactive conformation in the abl tyrosine kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

The cellular geography of aurora kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Mitotic mechanics: the auroras come into view

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

The Aurora kinases: role in cell transformation and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Aurora-kinase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Homoharringtonine for the treatment of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Janus kinase 2: a critical target in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Crystal structure of the T315I mutant of AbI kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

CD13/APN regulates endothelial invasion and filopodia formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Drug resistance in cancer: principles of emergence and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1387

10.1586/14737140.8.9.1387

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18759691